
Core Viewpoint - SeaStar Medical Holding Corporation (NASDAQ: ICU) is facing allegations of issuing materially false and misleading statements regarding its compliance controls and financial reporting, which may lead to a restatement of financial statements and an overstatement of its business prospects [2]. Group 1 - The class period for the allegations is from October 31, 2022, to March 26, 2024 [2]. - Allegations include deficiencies in compliance controls related to the Humanitarian Device Exemption (HDE) Application and the likelihood of FDA disapproval of the application in its current form [2]. - The company is accused of downplaying the severity of deficiencies in its financial controls and overstating efforts to remediate these issues [2]. Group 2 - SeaStar is likely to restate one or more previously issued financial statements due to improper accounting for certain outstanding warrants and a prepaid forward agreement [2]. - The company's public statements regarding its post-merger business and financial prospects are claimed to be materially false and misleading [2]. - Shareholders are encouraged to register for the class action by September 6, 2024, to monitor the case's progress [3].